EA201690205A1 - Сайт-специфические химико-ферментативные модификации белков - Google Patents
Сайт-специфические химико-ферментативные модификации белковInfo
- Publication number
- EA201690205A1 EA201690205A1 EA201690205A EA201690205A EA201690205A1 EA 201690205 A1 EA201690205 A1 EA 201690205A1 EA 201690205 A EA201690205 A EA 201690205A EA 201690205 A EA201690205 A EA 201690205A EA 201690205 A1 EA201690205 A1 EA 201690205A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- proteins
- site
- enmentative
- modifications
- specific chemical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D229/00—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms
- C07D229/02—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms containing three-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/08—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Настоящее изобретение относится к способам и реагентам для использования в сайт-специфической модификации белков, имеющих остатки лизина, с помощью функционализированных пептидов путем использования химико-ферментативной реакции, опосредуемой микробной трансглютаминазой. Функционализированные белки можно использовать для исследований или терапевтического применения.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361845273P | 2013-07-11 | 2013-07-11 | |
US201462016044P | 2014-06-23 | 2014-06-23 | |
PCT/US2014/046409 WO2015006728A2 (en) | 2013-07-11 | 2014-07-11 | Site-specific chemoenzymatic protein modifications |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201690205A1 true EA201690205A1 (ru) | 2016-12-30 |
Family
ID=51298955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201690205A EA201690205A1 (ru) | 2013-07-11 | 2014-07-11 | Сайт-специфические химико-ферментативные модификации белков |
Country Status (12)
Country | Link |
---|---|
US (4) | US9359400B2 (ru) |
EP (2) | EP3613755A1 (ru) |
JP (1) | JP6739333B2 (ru) |
KR (1) | KR20160040556A (ru) |
CN (1) | CN105593238B (ru) |
AU (1) | AU2014286990A1 (ru) |
BR (1) | BR112016000585A2 (ru) |
CA (1) | CA2918076A1 (ru) |
EA (1) | EA201690205A1 (ru) |
ES (1) | ES2756526T3 (ru) |
MX (1) | MX2016000393A (ru) |
WO (1) | WO2015006728A2 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201690205A1 (ru) | 2013-07-11 | 2016-12-30 | Новартис Аг | Сайт-специфические химико-ферментативные модификации белков |
US10588980B2 (en) * | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
BR112018012388A2 (pt) * | 2015-12-18 | 2018-12-04 | Eisai R&D Management Co., Ltd. | imunoglobulinas conjugadas de lisina terminal-c |
US11058757B2 (en) | 2016-03-31 | 2021-07-13 | Pogona, LLC | Saccharide-polypeptide conjugate compositions and methods of use thereof |
BR112018075253A2 (pt) * | 2016-06-10 | 2019-04-30 | Eisai R&D Management Co., Ltd. | imunoglobulinas conjugadas com lisina |
MX2019002489A (es) | 2016-09-02 | 2019-10-21 | Sanofi Pasteur Inc | Vacuna contra neisseria meningitidis. |
CA3048981A1 (en) | 2016-12-30 | 2018-07-05 | Sutrovax, Inc. | Polypeptide-antigen conjugates with non-natural amino acids |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
WO2023244963A2 (en) * | 2022-06-16 | 2023-12-21 | The General Hospital Corporation | Bicyclononyne reagents for cell imaging |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPH0665280B2 (ja) | 1987-03-04 | 1994-08-24 | 味の素株式会社 | タンパクゲル化剤及びそれを用いるタンパクのゲル化方法 |
DE4022267C2 (de) | 1990-07-12 | 1994-09-15 | Degussa | N-Acyldipeptide und deren Verwendung |
JP2849773B2 (ja) | 1990-08-27 | 1999-01-27 | 天野製薬株式会社 | ストレプトミセス属由来のトランスグルタミナーゼの製造法 |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
US5425946A (en) | 1992-08-31 | 1995-06-20 | North American Vaccine, Inc. | Vaccines against group C Neisseria meningitidis |
DK0658118T3 (da) | 1992-08-31 | 2002-05-06 | Baxter Healthcare Sa | Vaccine mod Neisseria meningitidis, gruppe C |
US5508191A (en) | 1993-07-05 | 1996-04-16 | Takeda Chemical Industries, Ltd. | Mutant strains of agrobacterium for producing β-1,3-glucan |
JP3720363B2 (ja) | 1994-08-26 | 2005-11-24 | ノボザイムス アクティーゼルスカブ | 微生物のトランスグルタミナーゼ、それらの産生及び使用 |
WO1996010089A1 (fr) | 1994-09-29 | 1996-04-04 | Ajinomoto Co., Inc. | Modification d'un peptide et d'une proteine |
EP0871712B1 (en) | 1995-01-19 | 2003-08-27 | Novozymes A/S | Transglutaminases from oomycetes |
JP3669390B2 (ja) | 1995-02-09 | 2005-07-06 | 味の素株式会社 | バチルス属細菌由来のトランスグルタミナーゼ |
US6284884B1 (en) | 1995-06-07 | 2001-09-04 | North American Vaccine, Inc. | Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof |
EP0815833B1 (en) | 1996-06-24 | 2003-04-09 | Givaudan SA | Malodour preventing agents |
CN1231675A (zh) | 1996-09-26 | 1999-10-13 | 味之素株式会社 | 修饰的生理活性蛋白及含有该蛋白的药物组合物 |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
US6919076B1 (en) | 1998-01-20 | 2005-07-19 | Pericor Science, Inc. | Conjugates of agents and transglutaminase substrate linking molecules |
US6958148B1 (en) | 1998-01-20 | 2005-10-25 | Pericor Science, Inc. | Linkage of agents to body tissue using microparticles and transglutaminase |
US6267957B1 (en) | 1998-01-20 | 2001-07-31 | Howard Green | Attaching agents to tissue with transglutaminase and a transglutaminase substrate |
US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
MXPA03006561A (es) | 2001-01-23 | 2004-10-15 | Aventis Pasteur | Vacuna del conjugado proteina-polisacarido meningococico, multivalente. |
US7605175B2 (en) | 2001-03-02 | 2009-10-20 | Gpc Biotech Ag | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
JP2003199569A (ja) | 2001-12-17 | 2003-07-15 | Food Industry Research & Development Inst | ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ |
DK1777236T3 (en) | 2002-03-26 | 2017-02-27 | Glaxosmithkline Biologicals Sa | MODIFIED SUCCARIDES WHICH IMPROVED WATER STABILITY FOR USE AS A MEDICINE |
GB0211118D0 (en) | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
EP1787661A1 (en) | 2004-09-10 | 2007-05-23 | Toray Industries, Inc. | Medicinal preparation |
WO2006050341A2 (en) | 2004-11-01 | 2006-05-11 | The Brigham And Women's Hospital, Inc. | Modified streptococcal polysaccharides and uses thereof |
GB0502096D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Purification of streptococcal capsular polysaccharide |
WO2006134148A2 (en) * | 2005-06-15 | 2006-12-21 | Novo Nordisk Health Care Ag | Transglutaminase mediated conjugation of growth hormone |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
CN101809032A (zh) * | 2007-08-24 | 2010-08-18 | 诺沃-诺迪斯克有限公司 | 用于选择性修饰蛋白质的方法 |
WO2009032247A1 (en) * | 2007-08-30 | 2009-03-12 | Northwestern University | Synthetic peptide and peptide conjugates and related tissue coupling methods via transglutaminase enzyme |
DE102007044296A1 (de) * | 2007-09-17 | 2009-03-19 | Hans-Lothar Prof. Dr. Fuchsbauer | Strukturmodulator von Proteinen |
US8137925B2 (en) * | 2007-11-09 | 2012-03-20 | Massachusetts Institute Of Technology | Methods and compositions for protein labeling using lipoic acid ligases |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
WO2012082618A2 (en) | 2010-12-13 | 2012-06-21 | Immunomedics, Inc. | Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules |
US20110184147A1 (en) | 2008-07-04 | 2011-07-28 | Kyushu University, National University Corporation | Enzyme substrate for labeling of protein |
CN102333788A (zh) * | 2009-02-19 | 2012-01-25 | 诺沃—诺迪斯克有限公司 | 因子viii的修饰 |
FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
US8853151B2 (en) | 2009-06-30 | 2014-10-07 | The Regents Of The University Of Michigan | Pro-drug complexes and related methods of use |
US20110020837A1 (en) | 2009-07-07 | 2011-01-27 | Universiteit Utrecht Holding B.V. | Method for isolating or identifying a target protein interacting with a lipid in a cell |
EP2515914A4 (en) | 2009-12-23 | 2013-09-11 | Scripps Research Inst | BIOCONJUGATION OF TYROSINE BY EYE REACTIONS IN AQUEOUS MEDIA |
ES2527536T7 (es) | 2010-04-27 | 2016-03-08 | Synaffix B.V. | Compuestos de ciclooctina fusionada y su uso en reacciones clic sin metales |
WO2012006475A1 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
EP2590989A2 (en) | 2010-07-09 | 2013-05-15 | Universite de Bretagne Occidentale | Modular construction of lipophospholipids |
CN103298949A (zh) | 2010-10-29 | 2013-09-11 | 生命科技公司 | 生物素衍生物 |
CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
CN103502275A (zh) | 2010-12-07 | 2014-01-08 | 耶鲁大学 | 融合蛋白的小分子疏水性标记和引起的其降解 |
WO2012142659A1 (en) | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
FR2981352B1 (fr) | 2011-10-17 | 2015-07-03 | Centre Nat Rech Scient | Procede de synthese de proteines |
AU2012344702A1 (en) | 2011-12-01 | 2014-06-19 | Angiochem Inc. | Targeted lysosomal enzyme compounds |
JP5509440B2 (ja) * | 2012-06-22 | 2014-06-04 | 国立大学法人九州大学 | タンパク質−核酸複合体の製造方法および標的物の検出方法 |
CN105517577A (zh) * | 2013-06-21 | 2016-04-20 | 先天制药公司 | 多肽的酶促偶联 |
EA201690205A1 (ru) | 2013-07-11 | 2016-12-30 | Новартис Аг | Сайт-специфические химико-ферментативные модификации белков |
-
2014
- 2014-07-11 EA EA201690205A patent/EA201690205A1/ru unknown
- 2014-07-11 BR BR112016000585A patent/BR112016000585A2/pt not_active Application Discontinuation
- 2014-07-11 AU AU2014286990A patent/AU2014286990A1/en not_active Abandoned
- 2014-07-11 ES ES14748350T patent/ES2756526T3/es active Active
- 2014-07-11 EP EP19187438.7A patent/EP3613755A1/en not_active Withdrawn
- 2014-07-11 CN CN201480046805.8A patent/CN105593238B/zh active Active
- 2014-07-11 US US14/329,758 patent/US9359400B2/en active Active
- 2014-07-11 KR KR1020167003053A patent/KR20160040556A/ko not_active Application Discontinuation
- 2014-07-11 MX MX2016000393A patent/MX2016000393A/es unknown
- 2014-07-11 CA CA2918076A patent/CA2918076A1/en not_active Abandoned
- 2014-07-11 WO PCT/US2014/046409 patent/WO2015006728A2/en active Application Filing
- 2014-07-11 JP JP2016525817A patent/JP6739333B2/ja active Active
- 2014-07-11 EP EP14748350.7A patent/EP3019515B1/en active Active
-
2016
- 2016-05-02 US US15/144,397 patent/US20160237116A1/en not_active Abandoned
-
2018
- 2018-11-29 US US16/204,557 patent/US10975120B2/en active Active
-
2021
- 2021-04-12 US US17/228,284 patent/US20220089639A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112016000585A2 (pt) | 2018-03-20 |
EP3613755A1 (en) | 2020-02-26 |
US9359400B2 (en) | 2016-06-07 |
EP3019515A2 (en) | 2016-05-18 |
US20220089639A1 (en) | 2022-03-24 |
US20160237116A1 (en) | 2016-08-18 |
WO2015006728A2 (en) | 2015-01-15 |
AU2014286990A1 (en) | 2016-02-11 |
CA2918076A1 (en) | 2015-01-15 |
EP3019515B1 (en) | 2019-08-21 |
US20150017192A1 (en) | 2015-01-15 |
KR20160040556A (ko) | 2016-04-14 |
ES2756526T3 (es) | 2020-04-27 |
WO2015006728A3 (en) | 2015-03-12 |
JP2016526574A (ja) | 2016-09-05 |
MX2016000393A (es) | 2016-10-26 |
US20190300570A1 (en) | 2019-10-03 |
US10975120B2 (en) | 2021-04-13 |
JP6739333B2 (ja) | 2020-08-12 |
CN105593238B (zh) | 2020-09-08 |
CN105593238A (zh) | 2016-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201690205A1 (ru) | Сайт-специфические химико-ферментативные модификации белков | |
MX2021008816A (es) | Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, anticuerpos de union a interleucina 8 (il-8) y usos de los mismos. | |
MX2016016886A (es) | Anticuerpos anti-axl. | |
EA201492101A1 (ru) | Антитела против fcrn | |
EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
EA201591515A1 (ru) | Полипептиды il-22, химерные белки il-22 fc и их применение | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
MX2019007921A (es) | Nuevos agentes de union a ha. | |
PH12015501846A1 (en) | Novel antibody conjugates and uses thereof | |
EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
EA201600474A1 (ru) | Комбинированная терапия с использованием антитела к ang2 и агониста cd40 | |
EA201391041A1 (ru) | Растворимые в воде мембранные белки и способы их получения и применения | |
UY34254A (es) | Proteínas y péptidos modificados. | |
EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 | |
EA201400579A1 (ru) | Антитела к il-36r | |
UY35444A (es) | Anticuerpos anti-tnf alfa mutados y métodos para su utilización | |
PH12015501687A1 (en) | Novel binding proteins from pcsk9 | |
EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
EA201691374A1 (ru) | Инсулин длительного действия и его применение | |
AR095977A1 (es) | Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína | |
EA201690503A1 (ru) | Антитела | |
EA201690992A1 (ru) | Антитела, специфичные к fcrn | |
MX2017007381A (es) | Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano. | |
EA201301090A1 (ru) | Антидоты антикоагулянтов |